slides · global inventory
Compare Peers
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,820
Current window 7,231-7,260
Pages 328
Rows per page 30
Slide function
7,231-7,260 of 9,820
32
The slide highlights selectivity and potency, using arrows to indicate performance relative to the competitor.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
45
The slide uses a matrix-like layout to compare drug candidates by development stage and company, with a callout box for competitive advantages.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
47
The slide uses a contrast-based layout to frame the subject as a winner in a difficult therapeutic space.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
54
The slide uses a comparative layout contrasting a list of competitor assets with the specific benefits of the company's own asset (ERAS-601).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
20
The chart uses a diverging bar structure to show relative performance against peers.Etsy | Results Presentation Deck | 35 slides · Etsy
Conference presentation Investor relations 1 hit
30
The slide uses a comparison framework to justify a merger or partnership by showing how the two entities fill each other's gaps.Eutelsat | Investor Presentation Deck | 63 slides · Eutelsat Group
Conference presentation Investor relations Beat · Solution1 hit
09
The slide uses a table to highlight the unique value proposition of four specific clinical programs.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
35
The table uses a color-coded heatmap to indicate performance against criteria.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
42
The slide uses a traffic-light color coding system to highlight the competitive advantage of the company's drug candidate.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
52
The slide uses a traffic-light color coding system to indicate performance against criteria.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
68
The slide uses a heatmap-style table to visualize performance against criteria, with a specific callout box around the UGT1A1 row.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
73
The table uses a heatmap-style color coding (red/green) to indicate risk levels for UGT1A1 inhibition parameters.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
19
The table uses a heatmap-style color coding (red for high risk, green for low risk) to visualize safety metrics.Exscientia | Results Presentation Deck | 24 slides · Exscientia
Conference presentation Investor relations 1 hit
08
The slide uses a grouping strategy to categorize competitors and show valuation multiples for specific segments.FiscalNote | Investor Presentation Deck | 33 slides · FiscalNote
Pitch deck Investor relations Beat · Competition1 hit
14
The slide contrasts a chemotherapy-based approach (SMDC) with a radioligand therapy (RLT) approach, highlighting the superior PSA response in the RLT cohort.Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides · Fusion Pharmaceuticals
Pitch deck Investor relations 1 hit
09
The slide uses a table-like layout to compare market sizes and brand presence across different lifestyle verticals.Hagerty | Investor Presentation Deck | 24 slides · Hagerty
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
The chart uses a highlight color for Hugo Boss to emphasize its position at the top of the peer set.Hugo Boss | Investor Presentation Deck | 104 slides · Hugo Boss
Conference presentation Investor relations Beat · Solution1 hit
08
Uses a traffic light system (green, yellow, red) to indicate performance/status.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
06
The slide uses a process-flow diagram to contrast personalized autologous therapy with off-the-shelf bispecific therapy.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
14
The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
17
The slide uses a multi-panel line chart to compare clinical outcomes across three different therapies.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
20
The slide uses a grouped bar chart format to compare clinical outcomes across different therapeutic agents.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
21
The slide uses a table to contrast treatment efficacy and patient growth across disease stages.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
22
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
31
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
32
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red) categorized by prior BCMA treatment status.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
33
The table compares NXC-201 against various CAR-T therapies, highlighting patient characteristics, efficacy (ORR, CR), and safety (ICANS, CRS) metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
37
The table highlights specific clinical safety metrics including onset and duration for CRS and ICANS, as well as the use of Tocilizumab and Dexamethasone.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
59
Highlights NXC-201's lower fludarabine dose and compares infusion timing across therapies.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit